article thumbnail

NHC Comments on Draft CY 2025 Part D Redesign Program Instructions

Putting Patients First Blog

Ensure Comprehensive Transparency in Formulary Management: Provide clear, comprehensive guidelines to Part D plans to ensure transparency in plan coverage, tiering, and utilization management (UM) policies, offering safeguards against practices that could restrict access to necessary treatments.

article thumbnail

NHC Comments on Help Committee Pandemic Preparedness RFI

Putting Patients First Blog

Provisions to Ensure Coverage During Future PHEs The pandemic has underscored the importance of meaningful, affordable health insurance coverage. Making sure that the greatest number of people possible have coverage during a PHE is critical to assuring that patients and our health care system are protected during a PHE.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

NHC’s comments in response to the 2025 Notice of Benefit and Payment Parameters (NBPP)

Putting Patients First Blog

Making available more specific information about total costs and coverage will ensure that all consumers have comprehensive information to help them make smart health care decisions. These resources should aim to clarify insurance terms and concepts, aiding consumers in navigating the complexities of selecting a health plan.

article thumbnail

NHC Comments on Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies

Putting Patients First Blog

Under the new Manufacturer Discount Program, manufacturers will be required to provide discounts on applicable drugs during the initial coverage phase and catastrophic phase of the defined standard Part D drug benefit.

article thumbnail

Kaia Health gets $75m for digital solution to strains and pains of pandemic workplace

pharmaphorum

To say that Kaia Health has had a busy 2020 is an understatement. Officially launched in 2016, Kaia’s technology can now be accessed by 60 million patients worldwide and it claims to be the biggest player in digital MSK in terms of coverage. The benefits of insurance firms are focused on main HQ offices.”. About the author.

article thumbnail

The US biosimilar market: Predictions for 2021

pharmaphorum

In 2020, we saw seven of the 20 biosimilars currently available in the US launch. The United States biosimilar market experienced a significant increase in competition in 2020. As a result of the regulatory changes that occurred in March 2020, the first potential insulin biosimilar is on the horizon. million patients.

article thumbnail

Specialty pharma’s next big opportunity: it’s time for patient access to adopt an open protocol

pharmaphorum

In January 2020, the financial conglomerate Visa announced it was acquiring a relatively unknown startup, Plaid, for $5.3 Corporate acquisitions like these are not uncommon, but someone at the United States Department of Justice took notice of this announcement. Visa had established a stranglehold on financial transactions.

HIPAA 98